Fisher Asset Management’s Sutro Biopharma STRO Stock Holding History

Fisher Asset Management’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Hold	35,295	–	–	﹤0.01%	685
2026 Q1	$879K	Sell	35,295 -10	-0%	-$181	﹤0.01%	703
2025 Q4	$408K	Buy	35,305 +10	+0%	+$95	﹤0.01%	815
2025 Q3	$306K	Hold	35,295	–	–	﹤0.01%	890
2025 Q2	$252K	Hold	35,295	–	–	﹤0.01%	918
2025 Q1	$230K	Buy	35,295 +8,161	+30%	+$129K	﹤0.01%	946
2024 Q4	$499K	Hold	27,134	–	–	﹤0.01%	775
2024 Q3	$939K	Hold	27,134	–	–	﹤0.01%	668
2024 Q2	$795K	Buy	27,134 +7,482	+38%	+$296K	﹤0.01%	708
2024 Q1	$1.11M	Hold	19,652	–	–	﹤0.01%	673
2023 Q4	$843K	Hold	19,652	–	–	﹤0.01%	712
2023 Q3	$682K	Hold	19,652	–	–	﹤0.01%	802
2023 Q2	$914K	Buy	+19,652	New	+$978K	﹤0.01%	793

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Fisher Asset Management's STRO Position: Q2 2026 in Review

Fisher Asset Management held its Sutro Biopharma (STRO) position steady in Q2 2026 at 35,295 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Fisher Asset Management first reported a position in STRO in Q2 2023 and has held it in 13 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Fisher Asset Management held 35,295 shares of Sutro Biopharma worth $1.17M as of Q2 2026.
Fisher Asset Management left its Sutro Biopharma share count unchanged in Q2 2026.
Sutro Biopharma made up ﹤0.01% of Fisher Asset Management's portfolio in Q2 2026, its #685 holding.
Fisher Asset Management first reported a position in Sutro Biopharma in Q2 2023 and has held it in 13 quarters since.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.